LifeSci Capital Sticks to Their Buy Rating for Liquidia Technologies (LQDA)
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Gaurav Maini maintained a Buy rating on Liquidia Technologies (LQDA) with a $101.00 price target. Maini, who has a 93.75% success rate, covers the Healthcare sector. The stock currently holds a Strong Buy consensus among analysts with an average price target of $87.29.
In a report released today, Gaurav Maini from LifeSci Capital maintained a Buy rating on Liquidia Technologies, with a price target of $101.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Maini covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Tectonic Therapeutic, and Liquidia Technologies. According to TipRanks, Maini has an average return of 28.6% and a 93.75% success rate on recommended stocks.
Liquidia Technologies has an analyst consensus of Strong Buy, with a price target consensus of $87.29.